Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects.
The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers. All soluble forms showed a rapid absorption profile, peak plasma salicylic acid levels being attained after about 30 min on average and without statistically significant differences among the solutions tested. As compared to the soluble formulations, acetylsalicylic acid given as tablets resulted in slower absorption, with peak plasma salicylic acid levels being reached more than 1 h after dosing. Despite these differences in time course of plasma level profiles, the extent of absorption was similar for all formulations. Apart from the potential advantages in terms of improved gastric tolerability, the increased rate of absorption of aspirin solutions is therapeutically useful whenever a rapid onset of action is required. In this respect, the kinetic pattern of the innovative formulation compares favourably with that of other available soluble dosage forms.
Gatti
G
G
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Barzaghi
N
N
Attardo Parrinello
G
G
Vitiello
B
B
Perucca
E
E
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D002021:Buffers; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D012459:Salicylates / Q000097:blood / Q000493:pharmacokinetics*; D020156:Salicylic Acid; D012995:Solubility; D013607:Tablets
D002021:Buffers; D012459:Salicylates; D013607:Tablets; D008239:Lysine; D020156:Salicylic Acid; D001241:Aspirin; C010395:acetylsalicylic acid lysinate